ICG124 / iCell Gene Therap - LARVOL DELTA

"@kristen_larocco @Gemini21BLM @DrTedros @gabby_UCMaroon @rrichterr @TCRG2012 @PeepMomma @CanelaCoffe @CowboysBabyGurl @garychristou @garychristou @EricG1247 @GeorgeTakei @golfexaminer @UROCKlive1 @priscilagural @StayingSusin @marissahiggins_ @bhight3 @WHO @WHCOVIDResponse" (@priscilagural)

Novel Coronavirus Disease

"@ElvenSong1 @golfexaminer @ERACoalition @DrEddyMD @DoYouEvenLif @EricG1247 @AllenLEllison @DoctorBerlin @electroboyusa @EMaxfieldMoen @EnsolPresley @priscilagural @DrTomFrieden @DrEricDing @dr_cmm @DemNevada @DoctorRamani @drLisaM @DrMitchAMedina @DrTedros @TullyTime9 @Dr_Arlan" (@priscilagural)

"@Johnldeboer @DrTedros @AliNouriPhD @essenviews @CDAngeloAuthor @TCRG2012 @priscilagural @AllenLEllison @EmiliWinst @AnnaNJNY @fightfor15 @EricG1247 @ray_osa @GrandpaSnarky @srfn_fitness @crzyfkinworld @alex96_cityboy @johnfeal2 @fake_biden @ResisterChic @LouGarza86 @czarim1" (@priscilagural)

CD5CAR-T: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: iCell Gene Therapeutics; Not yet recruiting ➔ Recruiting; Trial completion date: Nov 2022 ➔ Nov 2023; Trial primary completion date: Nov 2022 ➔ Nov 2023

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma

CD5CAR-T: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: iCell Gene Therapeutics

New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma